Search
Showing results for "preterm birth lungs"
Modulation of ASL pH has been proposed as a therapy for CF. However, evidence that ASL pH is reduced in CF is limited and conflicting.
Bronchiectasis is a chronic lung disease that impairs quality of life and reduces life expectancy.
Help us discover a way to expand protection for the next generation.
Treatment for pulmonary exacerbations of cystic fibrosis (CF) can produce a range of positive and negative outcomes. Understanding which of these outcomes are achievable and desirable to people affected by disease is critical to agreeing to goals of therapy and determining endpoints for trials.
A significant proportion of chronic obstructive pulmonary disease exacerbations are strongly associated with rhinovirus infection (HRV). In this study, we combined long-term cigarette smoke exposure with HRV infection in a mouse model.
The method outlined in this article is a customization of the whole exhaust exposure method generated by Mullins et al. (2016) using reprogrammed primary human airway epithelial cells as described by Martinovich et al. (2017). It has been used successfully to generate recently published data (Landwehr et al. 2021). The goal was to generate an exhaust exposure model where exhaust is collected from a modern engine, real-world exhaust concentrations are used and relevant tissues exposed to assess the effects of multiple biodiesel exposures.
Biodiesel is promoted as a sustainable replacement for commercial diesel. Biodiesel fuel and exhaust properties change depending on the base feedstock oil/fat used during creation. The aims of this study were, for the first time, to compare the exhaust exposure health impacts of a wide range of biodiesels made from different feedstocks and relate these effects with the corresponding exhaust characteristics.
The Respiratory Environmental Health team conducts research in early life determinants of lung growth and development, respiratory environmental health, and mechanisms of airway dysfunction in asthma and other respiratory disease.
Researchers developing a world-first treatment that targets an underlying cause of asthma have secured a $499,640 grant from the Future Health, Research and Innovation Fund – Innovation Seed Fund.
Research reveals that friendly bacteria may help reduce flu symptoms, offering new insights into potential treatments and enhancing our understanding of immune health.